Compare iShares MSCI Canada (TSX) (EWC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares MSCI Canada (TSX) trades at $59.18 (market cap $7.17B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: iShares MSCI Canada (TSX) is the larger of the two by market cap, and iShares MSCI Canada (TSX) is more actively traded (3,409,217 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 57 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EWC | TVTX | |
|---|---|---|
Market Cap | $7.17B | $4.88B |
Volume | 3,409,217 | 1,668,577 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $67.52 |
52-Week Low | $49.72 | $26.79 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $59.91, up 0.77% today, with a bullish technical signal from moving averages but neutral oscillators. The stock faces support at $59 and resistance at $60. Recent news highlights Canada's trade tensions with the U.S. and potential EU associate membership, impacting market sentiment.
Outlook is clouded by trade policy uncertainty, though diversification efforts with India and Europe offer growth avenues. Key risks include U.S. tariff escalations and economic volatility. Analyst sentiment is mixed, balancing geopolitical headwinds against strategic partnerships.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
